Indications for REBLOZYL:
Treatment of anemia in adults with beta thalassemia who require regular red blood cell (RBC) transfusions.
Limitations of Use:
Not for use as a substitute for RBC transfusions in patients who require immediate correction of anemia.
See full labeling. Dosing requiring larger reconstituted volume (>1.2mL), divide dose into separate similar volume injections and into separate sites (eg, upper arm, thigh, and/or abdomen). Give by SC inj. Initially 1mg/kg once every 3 weeks; if RBC transfusion burden is not achieved after ≥2 consecutive doses, increase to 1.25mg/kg. Discontinue if RBC transfusion burden does not decrease after ≥3 consecutive doses at the max dose or if unacceptable toxicity occurs.
Increased risk of thromboembolism (eg, smokers, splenectomy, hormone replacement therapy); monitor and treat promptly if occurs. Monitor BP. Assess hemoglobin (Hgb) results prior to each administration; if RBC transfusion occurred prior to dosing, consider the pretransfusion Hgb for dosing purposes. Embryo-fetal toxicity. Advise females of reproductive potential to use effective contraception during and for ≥3 months after the last dose. Pregnancy: exclude status prior to initiation. Nursing mothers: not recommended (during and for ≥3 months after the last dose).
Erythroid maturation agent.
Headache, bone pain, arthralgia, fatigue, cough, abdominal pain, diarrhea, dizziness; hypertension.